Michel Attal, MD, PhD Centre Hospitalier de Purpan Toulouse, France James R. Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, California, United States Jean-Luc Harousseau, MD Centre Hospitalier Universitaire Hôtel-Dieu Nantes, France Philippe Moreau, MD Centre Hospitalier Universitaire Hôtel-Dieu Nantes, France Gareth Morgan, MD, PhD Royal Marsden Hospital Surray, United Kingdom

Pathophysiology of myeloma bone disease                                                
    James R. Berenson, MD

Bone targeted therapy:  An important and emerging adjunct to current myeloma therapy                 
    Gareth Morgan, MD, PhD

Current therapeutic approaches in management of a newly diagnosed multiple myeloma patient
    Philippe Moreau, MD

IMiDs: Emerging concepts in maintenance therapy  
    Michel Attal, MD, PhD

What’s next for myeloma therapy?                                                              
    Jean-Luc Harousseau, MD

                                       

This educational activity has been developed to provide hematology specialists based outside of the United States with a comprehensive overview of the recent advances in the treatment of multiple myeloma from an international perspective.